

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
(Incorporated in the Cayman Islands with limited liability)  
(Stock code: 1548)

**INSIDE INFORMATION  
POSITIVE PROFIT ALERT**

This announcement is made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the disclosure obligations under Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors of the Company (the “**Board**”) wishes to inform shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the latest unaudited management accounts of the Group for the six months ended June 30, 2025 (the “**Reporting Period**”), and the information currently available to the Company, the Group is expected to record a substantial increase in profit before tax for the Reporting Period as compared to the six months ended June 30, 2024 (the “**Prior Period**”), excluding: (i) share of profits or losses from Legend Biotech Corporation (“**Legend**”) for the Reporting Period, and (ii) the loss from the discontinued operation for the Prior Period given Legend was deconsolidated from the Group on October 18, 2024.

On the adjusted basis, the Group is expected to record profit before tax of approximately US\$175.4 million to US\$204.6 million for the Reporting Period, whilst the loss before tax of the Group was approximately US\$127.9 million for the Prior Period. The expected increase in the profit before tax of the Group is principally derived from the following reasons:

- (1) The increase of license revenue: the Group is expected to record license revenue of no less than US\$182.2 million to US\$212.5 million, as compared to approximately US\$755,000 for the Prior Period. The increase of license revenue was mainly caused by the sublicense revenue generated from LaNova Medicines Ltd. (“**LaNova**”). The increase reflects the continued momentum of the Group’s diversified business mode and demonstrates ProBio’s ability to participate in the global value chain distribution through its leading technology and platforms. For details of payments received from LaNova, please refer to the announcement of the Company dated June 30, 2025.
- (2) The decrease of the non-cash fair value loss derived from Probio Series A Preferred Shares and Probio Series C Preferred Shares (each as defined in the Company’s annual report for the year of 2024). The Group is expected to record such fair value loss of approximately US\$13.1 million to US\$15.2 million, as compared to approximately US\$113.5 million for the Prior Period. Projections indicate no significant change of the fair value of Probio Technology Limited (“**ProBio**”) between June 30, 2025, and December 31, 2024.

The information contained in this announcement can only be treated as a preliminary assessment by the Board based on the latest unaudited management accounts of the Group and the information currently available, which are subject to finalisation and other potential adjustments, and is not based on any figures or information that has been audited, confirmed or reviewed by the auditor of the Company. Shareholders and potential investors of the Company are advised to read the interim results announcement of the Company for the Reporting Period, which is expected to be published before the end of August 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Genscript Biotech Corporation**  
**Robin Meng**  
*Chairman and Executive Director*

Hong Kong, July 22, 2025

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“**Mr. Robin Meng**”), Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Dr. Li Zhu and Ms. Ye Wang (“**Ms. Sally Wang**”); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“**Dr. Victor Shi**”).*